1
|
Saidoune F, Even G, Lamri Y, Chezel J, Gaston AT, Escoubet B, Papo T, Charles N, Nicoletti A, Sacre K. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus. Arthritis Rheumatol 2020; 73:255-264. [PMID: 32783382 DOI: 10.1002/art.41485] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 08/06/2020] [Indexed: 01/29/2023]
Abstract
OBJECTIVE Cardiovascular disease (CVD) is the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus, and anti-BAFF therapy has been approved for use in SLE. Since mature B cells also promote atherosclerosis, we undertook this study to evaluate, in a mouse model and in SLE patients, whether BAFF neutralization has an atheroprotective effect in SLE. METHODS The effect of BAFF on atherosclerosis associated with lupus was investigated in the atherosclerosis/lupus-prone apolipoprotein E-knockout D227K mouse model and in a cohort of SLE patients. Mice were treated with a blocking anti-BAFF monoclonal antibody (mAb), while fed a standard chow diet. Carotid plaque and carotid intima-media thickness were assessed by ultrasound at baseline and during follow-up in SLE patients who were asymptomatic for CVD. RESULTS Anti-BAFF mAb in ApoE-/- D227K mice induced B cell depletion, efficiently treated lupus, and improved atherosclerosis lesions (21% decrease; P = 0.007) in mice with low plasma cholesterol levels but worsened the lesions (17% increase; P = 0.06) in mice with high cholesterol levels. The atheroprotective effect of the BAFF-BAFF receptor signaling inhibition on B cells was counterbalanced by the proatherogenic effect of the BAFF-TACI signaling inhibition on macrophages. In SLE patients, blood BAFF levels were associated with subclinical atherosclerosis (r = 0.26, P = 0.03). Anti-BAFF mAb treatment had a differential effect on the intima-media thickness progression in SLE patients depending on body mass index. CONCLUSION Depending on the balance between lipid-induced and B cell-induced proatherogenic conditions, anti-BAFF could be detrimental or beneficial, respectively, to atherosclerosis development in SLE.
Collapse
Affiliation(s)
- Fanny Saidoune
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France
| | - Guillaume Even
- Université de Paris, INSERM U1148, Laboratoire d'Excellence Inflamex, Paris, France
| | - Yasmine Lamri
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France
| | - Julie Chezel
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| | - Anh-Thu Gaston
- Université de Paris, INSERM U1148, Laboratoire d'Excellence Inflamex, Paris, France
| | - Brigitte Escoubet
- Université de Paris, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| | - Thomas Papo
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| | - Nicolas Charles
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France
| | - Antonino Nicoletti
- Université de Paris, INSERM U1148, Laboratoire d'Excellence Inflamex, Paris, France
| | - Karim Sacre
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| |
Collapse
|
2
|
Saidoune F, Even G, Escoubet B, Chezel J, Charles N, Nicoletti A, Papo T, Sacré K. Effet JANUS de la neutralisation de BAFF sur la progression de la maladie athéromateuse associée au lupus. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Danial P, Dupont S, Escoubet B, Osborne-Pellegrin M, Jondeau G, Michel JB. Pulmonary haemodynamic effects of interatrial shunt in heart failure with preserved ejection fraction: a preclinical study. EUROINTERVENTION 2020; 16:434-440. [PMID: 31062698 DOI: 10.4244/eij-d-18-01100] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS The aim of this study was to evaluate the effect of the creation of a left-to-right interatrial shunt on pulmonary haemodynamics in rats with heart failure with preserved ejection fraction (HFPEF). METHODS AND RESULTS An interatrial communication (IAC) was created in 11 healthy rats (Lewis rats) and 11 rats which developed HFPEF (36-week-old spontaneously hypertensive rats [SHR]). Effects of the interatrial shunt were compared to 11 sham-operated Lewis and 11 sham-operated SHR. At 45 days post shunt, strain effect was observed in diastolic function (E/A ratio, p<0.001; isovolumetric relaxation time, p<0.001), left atrial volume (p=0.005) and pulmonary wall shear rate (WSR) (p=0.02) measured by Doppler echo. At sacrifice of the animals (60 days), a strain effect was also noted in elastin density (p=0.003) and eNOS protein expression (p=0.001). Interatrial shunt creation resulted in (i) an increase in pulmonary WSR (p=0.04) and a decrease in left atrial volume (p<0.001), (ii) an increase in elastin density (p<0.005), and (iii) an increase in eNOS protein expression (p=0.03). CONCLUSIONS Creation of a left-to-right atrial shunt in rats with HFPEF was effective in improving pulmonary haemodynamics. In addition, this study provides preliminary evidence of the potential risk of right volume overload and pulmonary hypertension due to atrial shunting.
Collapse
Affiliation(s)
- Pichoy Danial
- Denis Diderot University, Xavier Bichat Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | | | | | | | | | | |
Collapse
|
4
|
Saidoune F, Charles N, Chezel J, Escoubet B, Papo T, Nicoletti A, Sacre K. AB0140 BAFF NEUTRALIZATION HAS JANUS-FACED EFFECT ON ATHEROSCLEROSIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Cardiovascular diseases (CVD) are the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus and anti-BAFF therapy has been approved in SLE. Since mature B cells also promote atherosclerosis, BAFF neutralization is expected to have an atheroprotective effect in SLE.Objectives:The aim of our study was to test this hypothesis using a new mouse model with a mix susceptibility to lupus and atherosclerosis that received or not an anti-BAFF treatment, and in a cohort of SLE patients in whom we monitored carotid plaques, the B cell compartment and BAFF levels.Methods:The effect of BAFF on atherosclerosis associated with lupus was investigated in the atherosclerosis- and lupus-proneApoe°D227Kmouse model and in a cohort of SLE patients. Mice were treated with a blocking anti-BAFF monoclonal antibody (Ab), while fed with a standard chow diet. Carotid plaque and carotid intima media thickness were assessed by ultrasound at baseline and during follow-up in SLE patients asymptomatic for CVD.Results:Anti-BAFF Ab inApoe°D227Kmice i/ induced a B cell depletion, ii/ efficiently treated lupus, iii/improved atherosclerosis lesions in mice that had low plasma cholesterol levels but worsened the lesions in mice with high cholesterol levels. In that case, the atheroprotective effect of the BAFF-BAFFR signaling inhibition on B cells was counterbalanced by the proatherogenic effect of the BAFF-TACI signaling inhibition on macrophages. In SLE patients, BAFF blood levels were associated with subclinical atherosclerosis. Anti-BAFF Ab treatment had a differential effect on the intima media thickness progression in SLE patients depending on the body mass indexConclusion:Depending on the balance between metabolic- and B cell-induced proatherogenic conditions, anti-BAFF could be respectively detrimental or beneficial on atherosclerosis development in SLEAcknowledgments:Guillaume Even, Yasmine Lamri, Anh-Thu Gaston,Disclosure of Interests:Fanny Saidoune Grant/research support from: supported by a research partnerships between the academic and GlaxoSmithKline France.Anti-BAFF mAb (IgG1, clone 10F4B) in mice was provided by Glaxosmithkline, Nicolas Charles: None declared, Julie Chezel: None declared, Brigitte Escoubet: None declared, Thomas Papo: None declared, Antonino Nicoletti: None declared, karim sacre: None declared
Collapse
|
5
|
Gasser A, Chen YW, Audebrand A, Daglayan A, Charavin M, Escoubet B, Karpov P, Tetko I, Chan MWY, Cardinale D, Désaubry L, Nebigil CG. Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection. JACC CardioOncol 2019; 1:84-102. [PMID: 34396166 PMCID: PMC8352030 DOI: 10.1016/j.jaccao.2019.06.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 06/27/2019] [Indexed: 02/07/2023]
Abstract
Objectives This study investigated how different concentrations of doxorubicin (DOX) can affect the function of cardiac cells. This study also examined whether activation of prokineticin receptor (PKR)-1 by a nonpeptide agonist, IS20, prevents DOX-induced cardiovascular toxicity in mouse models. Background High prevalence of heart failure during and following cancer treatments remains a subject of intense research and therapeutic interest. Methods This study used cultured cardiomyocytes, endothelial cells (ECs), and epicardium-derived progenitor cells (EDPCs) for in vitro assays, tumor-bearing models, and acute and chronic toxicity mouse models for in vivo assays. Results Brief exposure to cardiomyocytes with high-dose DOX increased the accumulation of reactive oxygen species (ROS) by inhibiting a detoxification mechanism via stabilization of cytoplasmic nuclear factor, erythroid 2. Prolonged exposure to medium-dose DOX induced apoptosis in cardiomyocytes, ECs, and EDPCs. However, low-dose DOX promoted functional defects without inducing apoptosis in EDPCs and ECs. IS20 alleviated detrimental effects of DOX in cardiac cells by activating the serin threonin protein kinase B (Akt) or mitogen-activated protein kinase pathways. Genetic or pharmacological inactivation of PKR1 subdues these effects of IS20. In a chronic mouse model of DOX cardiotoxicity, IS20 normalized an elevated serum marker of cardiotoxicity and vascular and EDPC deficits, attenuated apoptosis and fibrosis, and improved the survival rate and cardiac function. IS20 did not interfere with the cytotoxicity or antitumor effects of DOX in breast cancer lines or in a mouse model of breast cancer, but it did attenuate the decreases in left ventricular diastolic volume induced by acute DOX treatment. Conclusions This study identified the molecular and cellular signature of dose-dependent, DOX-mediated cardiotoxicity and provided evidence that PKR-1 is a promising target to combat cardiotoxicity of cancer treatments.
Collapse
Key Words
- DMSO, dimethyl sulfoxide
- EC, endothelial cell
- EDPC, epicardium-derived progenitor cell
- EF, ejection fraction
- FS, fractional shortening
- GPCR, G-protein–coupled receptor
- HAEC, human aortic endothelial cell
- HF, heart failure
- HFrEF, heart failure with reduced ejection fraction
- MAPK, mitogen-activated protein kinase
- NRF2, nuclear factor, erythroid 2 like 2 (also known as NFE2L2)
- PECAM, platelet and endothelial cell adhesion molecule
- PKR1, prokineticin receptor-1 (also known as PROKR1)
- PKR1-KO, prokineticin receptor 1 knockout mice
- PROK1, prokineticin 1
- PROK2, prokineticin 2
- TUNEL, terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling
- breast cancer
- doxorubicin
- endothelial dysfunction
- epicardial progenitor cells
- heart failure
Collapse
Affiliation(s)
- Adeline Gasser
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| | - Yu-Wen Chen
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Anais Audebrand
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| | - Ayhan Daglayan
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| | - Marine Charavin
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| | - Brigitte Escoubet
- FRIM UMS37, Hospital Bichat assistance public-Paris Hospital, University of Paris Diderot, PRES Paris Cité, DHU FIRE, Inserm U1138, Paris, France
| | - Pavel Karpov
- Institute of Structural Biology, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Igor Tetko
- Institute of Structural Biology, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Michael W Y Chan
- Department of Biomedical Sciences, National Chung Cheng University, Chiayi, Taiwan
| | - Daniela Cardinale
- Cardioncology Unit, European Institute of Oncology, I.R.C.C.S., Milan Italy
| | - Laurent Désaubry
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| | - Canan G Nebigil
- Laboratory of Cardio-Oncology and Medicinal Chemistry, CNRS (FRE2033), Illkirch, France
| |
Collapse
|
6
|
David C, Divard G, Abbas R, Escoubet B, Chezel J, Chauveheid MP, Rouzaud D, Boutten A, Papo T, Dehoux M, Sacre K. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. Scand J Rheumatol 2019; 49:33-37. [PMID: 31161842 DOI: 10.1080/03009742.2019.1614213] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Objective: This study aimed to determine whether sCD163, a soluble macrophage marker up-regulated in numerous inflammatory disorders, is predictive of accelerated atherosclerosis associated with systemic lupus erythematosus (SLE).Methods: Carotid ultrasound was prospectively performed, at baseline and during follow-up, in 63 consecutive SLE patients asymptomatic for cardiovascular disease (CVD) and 18 volunteer health workers. Serum sCD163 level was determined at baseline using enzyme-linked immunosorbent assay. The primary outcome was the presence of a carotid plaque. Factors associated with carotid plaques were identified through multivariate analysis.Results: Despite a low risk for cardiovascular events according to Framingham score in both groups (2.1 ± 3.8% in SLE vs 2.1 ± 2.9% in controls; p = 0.416), ultrasound at baseline showed a carotid plaque in 23 SLE patients (36.5%) and two controls (11.1%) (p = 0.039). Multivariate analysis showed that SLE status increased the risk for carotid plaque by a factor of 9 (p = 0.017). In SLE patients, sCD163 level was high (483.7 ± 260.8 ng/mL vs 282.1 ± 97.5 ng/mL in controls; p < 0.001) and independently associated with carotid plaques, as assessed by stratification based on sCD163 quartile values (p = 0.009), receiver operating characteristics (p = 0.001), and multivariate analysis (p = 0.015). sCD163 at baseline was associated with the onset of carotid plaque during follow-up (3 ± 1.4 years) in SLE patients who had no carotid plaque at the first evaluation (p = 0.041).Conclusion: sCD163 is associated with progressing carotid plaque in SLE and may be a useful biomarker for accelerated atherosclerosis in SLE patients at apparent low risk for CVD.
Collapse
Affiliation(s)
- C David
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - G Divard
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - R Abbas
- Department of Epidemiology and Clinical Research, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - B Escoubet
- Departement of Physiology, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, INSERM, Paris, France
| | - J Chezel
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - M P Chauveheid
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - D Rouzaud
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - A Boutten
- Department of Metabolic and Cellular Biochemistry, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - T Papo
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France.,INSERM U1149 (French Institute of Health and Medical Research), University of Paris Diderot, Paris, France.,Hospital-University Department of Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases, FIRE, Paris, France
| | - M Dehoux
- Department of Metabolic and Cellular Biochemistry, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France
| | - K Sacre
- Departement of Internal Medicine, Bichat Hospital, University of Paris Diderot, PRES Sorbonne Paris Cité, APHP, Public Hospitals of Paris, Paris, France.,INSERM U1149 (French Institute of Health and Medical Research), University of Paris Diderot, Paris, France.,Hospital-University Department of Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases, FIRE, Paris, France
| |
Collapse
|
7
|
David C, Divard G, Abbas R, Escoubet B, Chezel J, Chauveheid M, Rouzaud D, Boutten A, Leçon-Malas V, Papo T, Dehoux M, Sacre K. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.04.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Bouleti C, Flamant M, Escoubet B, Arnoult F, Milleron O, Vidal-Petiot E, Langeois M, Ou P, Vrtovsnik F, Jondeau G. Risk of Ascending Aortic Aneurysm in Patients With Autosomal Dominant Polycystic Kidney Disease. Am J Cardiol 2019; 123:482-488. [PMID: 30477801 DOI: 10.1016/j.amjcard.2018.10.030] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 10/19/2018] [Accepted: 10/22/2018] [Indexed: 12/15/2022]
Abstract
In recent years, simple renal cysts have been associated with an increased risk of aortic aneurysms. There is little data regarding aortic dilation in patients with autosomal dominant polycystic kidney disease (ADPKD). The aim of this study was to compare Sinuses of Valsalva (SoV) and tubular ascending aorta diameters in ADPKD patients with matched controls. From 2008 to 2016, 61 consecutive ADPKD patients who had an echocardiogram performed in our institution were matched 1:1 with controls for sex, age, blood pressure, and β-blocker therapy use. SoV and tubular ascending aorta were measured at end-diastole, using the leading-edge to leading-edge convention. Paired t Tests were used for quantitative variables and McNemar-tests for qualitative variables. The mean age of patients was 56 ± 12 years, 54% were men, 38% received β-blockers, and mean systolic and diastolic BP were 137 ± 25 and 78 ± 19 mm Hg. SoV diameters were significantly larger in ADPKD patients than in controls (36.4 ± 4.1 vs 34.0 ± 3.7 mm, p <0.0001). The Z-scores (normalized for sex, age, and body surface area) were significantly higher in ADPKD patients, both for SoV and tubular ascending aorta. Moreover, aortic aneurysms, as defined by a Z score >2 standard deviations, were present in 27 ADPKD patients (44%) versus 9 controls (15%, p <0.001). In conclusion, there is an increased prevalence of aortic aneurysms in ADPKD patients as compared with controls matched for common confounding factors for aortic dilation.
Collapse
Affiliation(s)
- Claire Bouleti
- Department of Cardiology, Centre de Référence pour le syndrome de Marfan et apparentés, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; INSERM U1148 Bichat Hospital, Paris, France.
| | - Martin Flamant
- Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; Department of Physiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; INSERM U1149 Bichat Hospital, Paris, France
| | - Brigitte Escoubet
- Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; Department of Physiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; INSERM U1138 Bichat Hospital, Paris, France
| | - Florence Arnoult
- DHU Fire, Paris-Diderot University, France; Department of Physiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - Olivier Milleron
- Department of Cardiology, Centre de Référence pour le syndrome de Marfan et apparentés, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; INSERM U1148 Bichat Hospital, Paris, France
| | - Emmanuelle Vidal-Petiot
- Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; Department of Physiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; INSERM U1149 Bichat Hospital, Paris, France
| | - Maud Langeois
- Department of Cardiology, Centre de Référence pour le syndrome de Marfan et apparentés, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - Phalla Ou
- Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; Department of Radiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - François Vrtovsnik
- Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; INSERM U1149 Bichat Hospital, Paris, France; Department of Nephrology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - Guillaume Jondeau
- Department of Cardiology, Centre de Référence pour le syndrome de Marfan et apparentés, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France; Paris-Diderot University, Sorbonne Paris Cité, Paris, France; DHU Fire, Paris-Diderot University, France; INSERM U1148 Bichat Hospital, Paris, France
| |
Collapse
|
9
|
David C, Escoubet B, Abbas R, Chezel J, Chauveheid M, Papo T, Dehoux M, Sacré K. CD163 soluble est un marqueur d’athérome accéléré chez les patients lupiques à faible risque cardiovasculaire apparent. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Moussaoui A, Bouleti C, Flamant M, Escoubet B, Arnoult F, Milleron O, Vidal-Petiot E, Langeois M, Ou P, Vrtovsnik F, Jondeau G. Increased risk of aortic root aneurism in patient with autosomal dominant polycystic kidney disease. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Syvannarath V, Delbosc S, Escoubet B, Le Borgne-Moynnier M, Laschet J, Morvan M, Even G, Journee C, Nicoletti A, Caligiuri G. Treatment with a CD31 agonist peptide improves the outcome of experimental heart failure with either reduced or preserved ejection fraction. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Syvannarath V, Delbosc S, Escoubet B, Le Borgne-Moynier M, Khallou-Laschet J, Morvan M, Even G, Journee C, Nicoletti A, Caligiuri G. P126The administration of a CD31 agonist peptide exerts a beneficial effect in experimental heart failure with both reduced and preserved ejection fraction. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | - B Escoubet
- Hospital Bichat-Claude Bernard, Physiology, Paris, France
| | | | | | | | - G Even
- INSERM, U1148, Paris, France
| | | | | | | |
Collapse
|
13
|
Abstract
BACKGROUND Left ventricular (LV) torsion plays a key role in cardiac efficiency. In hypertension, aortic stiffening augments cardiac afterload. However, little is known about the links between LV regional contraction and aortic stiffness. We, therefore, investigated these relationships and their contribution to LV diastolic function. METHODS AND RESULTS The study included normotensive and hypertensive individuals with normal LV ejection. Apical, basal, and global LV rotation rate and LV global longitudinal strain were measured (2-dimensional speckle tracking echocardiography). Aortic stiffness was calculated from carotid-femoral pulse wave velocity, and LV relaxation was calculated from early diastolic mitral annulus motion. The ratio of basal or apical untwist/twist rates was calculated to assess relationships between aortic stiffness and LV torsion parameters. LV twist and untwist rates were greater in hypertensive than normotensive individuals because of increased basal twist (P<0.001) and untwist (P<0.001) rates. LV relaxation was reduced (early diastolic mitral annulus motion=7.4±1.9 versus 10.4±2.3 cm/s; P<0.001). In the whole population, basal untwist rate increased with aortic stiffening (R=0.43; P<0.001) and LV relaxation (R=0.41; P=0.001). The ratio of basal untwist/twist rate was positively correlated with carotid-femoral pulse wave velocity, and in the hypertensive group, was greater than in the control group and positively correlated to carotid-femoral pulse wave velocity(P<0.001). Results were independent of age, treatment, mean blood pressure, and indexed LV mass. CONCLUSIONS In hypertensive individuals, greater basal LV torsion was associated with increased aortic stiffness and improved diastolic function. These changes may compensate for the deleterious effects of aortic stiffening on LV relaxation.
Collapse
Affiliation(s)
- Jean-Barthelemy Gnakamene
- Department of Physiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France .,Centre de Diagnostic et Thérapeutique Cardiovasculaire, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Michel E Safar
- Centre de Diagnostic et Thérapeutique Cardiovasculaire, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.,Paris Descartes University, Paris, France
| | - Bernard I Levy
- INSERM U-970, Centre de Recherches Cardiovasculaire, Paris, France.,Vessels and Blood Institute, Hôpital Lariboisière, Paris, France
| | - Brigitte Escoubet
- Department of Physiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.,Pôle de Recherche et d'Enseignement Supérieur Sorbonne Paris Cité, Paris Diderot University, Paris, France.,INSERM U-1138, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
14
|
Bouleti C, Flamant M, Escoubet B, Arnoult F, Milleron O, Vidal-Petiot E, Langeois M, Vrtovsnik F, Jondeau G. P5245Autosomal polycystic kidney disease carries an increased risk of aortic root aneurysm. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Divard G, Abbas R, Chenevier-Gobeaux C, Chanson N, Escoubet B, Chauveheid MP, Dossier A, Papo T, Dehoux M, Sacre K. High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study. Arthritis Res Ther 2017; 19:132. [PMID: 28610589 PMCID: PMC5470230 DOI: 10.1186/s13075-017-1352-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 05/26/2017] [Indexed: 11/24/2022] Open
Abstract
Background Cardiovascular disease (CVD) is the main cause of death in systemic lupus erythematous (SLE) patients. The Framingham score underestimates the risk for CVD in this population. Our study aimed to determine whether serum high-sensitivity cardiac troponin T (HS-cTnT) might help to identify SLE patients at risk for CVD. Methods The presence of carotid plaques was prospectively assessed by ultrasound in 63 consecutive SLE patients asymptomatic for CVD and 18 controls. Serum HS-cTnT concentration was measured using the electrochemiluminescence method. Factors associated with carotid plaques were identified and multivariate analysis was performed. Results Framingham score was low in both SLE patients (median 1 (range 1–18%)) and controls (1 (1–13%)). Nevertheless, 23 (36.5%) SLE patients, but only 2 (11.1%) controls (p = 0.039), had carotid plaque detected by vascular ultrasound. In the multivariate analysis, only age (p = 0.006) and SLE status (p = 0.017) were independently associated with carotid plaques. Serum HS-cTnT concentration was detectable (i.e. >3 ng/L) in 37 (58.7%) SLE patients and 6 (33.3%) controls (p = 0.057). Interestingly, 87% of SLE patients with carotid plaques, but only 42.5% of SLE patients without plaques (p < 0.001), had detectable HS-cTnT. Conversely, 54.5% of SLE patients with detectable HS-cTnT, but only 11.5% with undetectable HS-cTnT (p < 0.001), had a carotid plaque. In the multivariate analysis, only body mass index (p = 0.006) and HS-cTnT (p = 0.033) were statistically associated with carotid plaques in SLE patients. Overall, the risk of having a carotid plaque was increased by 9 (odds ratio 9.26, 95% confidence interval 1.55–90.07) in SLE patients in whom HS-cTnT was detectable in serum. Conclusion Serum HS-cTnT level is high and associated with carotid plaques in SLE patients who are at an apparently low risk for CVD according to the Framingham score. HS-cTnT may be a useful biomarker for SLE-associated atherosclerosis.
Collapse
Affiliation(s)
- Gillian Divard
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Rachid Abbas
- Département d'Epidémiologie et recherche clinique, CIC-EC 1425, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris France; Univ Paris Diderot, PRES Sorbonne Paris Cité, UMR 1123 ECEVE, Paris, France
| | - Camille Chenevier-Gobeaux
- Département de Biochimie, Hôpital Cochin, Université Paris Descartes, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Noémie Chanson
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Brigitte Escoubet
- Département de Physiologie, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U1138, Paris, France
| | - Marie-Paule Chauveheid
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Antoine Dossier
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France
| | - Thomas Papo
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France.,INSERM U1149, Paris, France.,Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France
| | - Monique Dehoux
- Département de Biochimie Métabolique et Cellulaire, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Karim Sacre
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75018, Paris, France. .,INSERM U1149, Paris, France. .,Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France.
| |
Collapse
|
16
|
Divard G, Abbas R, Chenevier-Gobeaux C, Escoubet B, Chauveheid M, Dossier A, Dehoux M, Papo T, Sacré K. La troponine C ultrasensible est un biomarqueur d’athérosclérose accélérée chez les sujets lupiques. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Agoston-Coldea L, Kouaho S, Sacre K, Dossier A, Escoubet B, Chillon S, Laissy JP, Rouzet F, Kutty S, Extramiana F, Leenhardt A, Borie R, Crestani B, Ou P. High mass (>18g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Int J Cardiol 2016; 222:950-956. [PMID: 27526366 DOI: 10.1016/j.ijcard.2016.07.233] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 07/07/2016] [Accepted: 07/29/2016] [Indexed: 02/08/2023]
Abstract
BACKGROUND Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. METHODS Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE<18g, high LGE>18g) for comparison of MACE. RESULTS Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR=31.15, 95% CI 3.7-262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32months). Patients with high LGE had lower CMR-derived left (53.6±14.9 vs. 62.2±6.7, p<0.01) and right (49.1±11.5 vs. 56.4±9.2, p<0.05) ventricular ejection fractions. LGE mass of 18g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC=0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR=1.7, 95% CI 1.06 to 2.72, p=0.03). CONCLUSION In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE >18g was associated with MACE.
Collapse
Affiliation(s)
| | - Sylvain Kouaho
- Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - Karim Sacre
- Service de Médecine Interne, Hopital Bichat, APHP, University Paris Diderot, France
| | - Antoine Dossier
- Service de Médecine Interne, Hopital Bichat, APHP, University Paris Diderot, France
| | - Brigitte Escoubet
- Service d'Explorations Fonctionnelles, Hospital Bichat, APHP, University Paris Diderot, France
| | - Sylvie Chillon
- Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - Jean-Pierre Laissy
- Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - François Rouzet
- Service de Medecine Nucleaire, Hopital Bichat, APHP, University Paris Diderot, France
| | - Shelby Kutty
- Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - Fabrice Extramiana
- Service de Cardiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - Antoine Leenhardt
- Service de Cardiologie, Hopital Bichat, APHP, University Paris Diderot, France
| | - Raphael Borie
- Service de Pneumologie, Hopital Bichat, APHP; University Paris Diderot, France
| | - Bruno Crestani
- Service de Pneumologie, Hopital Bichat, APHP; University Paris Diderot, France
| | - Phalla Ou
- Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, France; Service de Radiologie, Hopital Bichat, APHP, University Paris Diderot, and Inserm 1148, Paris, France.
| |
Collapse
|
18
|
Sacre K, Escoubet B, Zennaro MC, Chauveheid MP, Gayat E, Papo T. Overweight Is a Major Contributor to Atherosclerosis in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Cross-Sectional Controlled Study. Medicine (Baltimore) 2015; 94:e2177. [PMID: 26632902 PMCID: PMC4674205 DOI: 10.1097/md.0000000000002177] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Cardiovascular disease (CVD) is the main cause of death in systemic lupus erythematosus (SLE) patients. We aimed to determine whether overweight (defined as a body mass index [BMI] > 25 kg/m(2)) contributed to subclinical atherosclerosis in SLE patients at low risk for CVD according to traditional factors. Wall thickness of the internal carotid artery (ICWT) measured at the carotid bulb and carotid plaques were assessed in 49 SLE patients asymptomatic for CVD and 49 controls matched on Framingham score. Factors associated to ICWT were identified and multivariate analysis was performed.SLE patients and controls displayed a low 10-year risk for CVD according to Framingham score (mean 1.9 ± 3.5 in SLE vs 1.8 ± 3.2% in controls, P = 0.37). ICWT (P < 0.001) and number of patients with carotid plaques (P = 0.015) were, however, higher in SLE patients as compared to controls. In multivariable analysis, SLE was an independent risk for a carotid atherosclerosis (OR [95% confidence interval, CI]: 3.53 [1.36-9.14]; P = 0.009). Older age, higher BMI, and higher Framingham score were associated with atherosclerosis in SLE patients in univariate analysis. In multivariate analysis, only the association with overweight remained significant (OR [95% CI]: 4.13 [1.02-16.75]; P = 0.047). Overweight is a major contributor to atherosclerosis in SLE patients at apparent low risk for CVD.
Collapse
Affiliation(s)
- Karim Sacre
- From the Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France (KS, M-PC, TP); INSERM U1149, Paris, France (KS, TP); Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France (KS, TP); Département de Physiologie, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U1138, Paris, France (BE); INSERM UMRS970, Paris Cardiovascular Research Center, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Département de Génétique, Paris, France (M-CZ); and Département d'Anesthésie-Réanimation, Hôpitaux Universitaires Saint Louis-Lariboisière, 2 UMR-S 942, INSERM, 3 Université Paris Diderot, Paris, France (EG)
| | | | | | | | | | | |
Collapse
|
19
|
Clement M, Charles N, Escoubet B, Guedj K, Chauveheid MP, Caligiuri G, Nicoletti A, Papo T, Sacre K. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J Autoimmun 2015; 63:59-67. [PMID: 26183767 DOI: 10.1016/j.jaut.2015.07.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 07/01/2015] [Accepted: 07/01/2015] [Indexed: 01/02/2023]
Abstract
Cardiovascular disease due to accelerated atherosclerosis is the leading cause of death in patients with systemic lupus erythematosus (SLE). Noteworthy, accelerated atherosclerosis in SLE patients appears to be independant of classical Framingham risk factors. This suggests that aggravated atherosclerosis in SLE patients may be a result of increased inflammation and altered immune responses. However, the mechanisms that mediate the acceleration of atherosclerosis in SLE remain elusive. Based on experimental data which includes both humans (SLE patients and control subjects) and rodents (ApoE-/- mice), we herein propose a multi-step model in which the immune dysfunction associated with SLE (i.e. high level of IFN-α production by TLR 9-stimulated pDCs) is associated with, first, an increased frequency of circulating pro inflammatory CD4+CXCR3+ T cells; second, an increased production of CXCR3 ligands by endothelial cells; third, an increased recruitment of pro-inflammatory CD4+CXCR3+ T cells into the arterial wall, and fourth, the development of atherosclerosis. In showing how SLE may promote accelerated atherosclerosis, our model also points to hypotheses for potential interventions, such as pDCs-targeted therapy, that might be studied in the future.
Collapse
Affiliation(s)
- Marc Clement
- INSERM U1148, Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
| | - Nicolas Charles
- INSERM U1149, Université Paris Diderot, Laboratoire d'excellence INFLAMEX, PRES Sorbonne Paris Cité, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
| | - Brigitte Escoubet
- Département de Physiologie, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Kevin Guedj
- INSERM U1148, Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
| | - Marie-Paule Chauveheid
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Giuseppina Caligiuri
- INSERM U1148, Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
| | - Antonino Nicoletti
- INSERM U1148, Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France
| | - Thomas Papo
- INSERM U1149, Université Paris Diderot, Laboratoire d'excellence INFLAMEX, PRES Sorbonne Paris Cité, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France; Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Karim Sacre
- INSERM U1149, Université Paris Diderot, Laboratoire d'excellence INFLAMEX, PRES Sorbonne Paris Cité, Paris, France; Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France; Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France.
| |
Collapse
|
20
|
Sacre K, Chauchard M, Escoubet B, Francois C, Vanderhaegen MC, Zennaro MC, Chauveheid MP, Papo T. AB0174 Overweight is an Independent Contributor to Atherosclerosis in Systemic Lupus Erythematosus Patients at Low Risk for Cardiovascular Disease: A Cross-Sectional Controlled Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Walker BR, Andrew R, Escoubet B, Zennaro MC. Activation of the hypothalamic-pituitary-adrenal axis in adults with mineralocorticoid receptor haploinsufficiency. J Clin Endocrinol Metab 2014; 99:E1586-91. [PMID: 24712576 DOI: 10.1210/jc.2014-1420] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
CONTEXT Mineralocorticoid receptors (MRs) contribute to the negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis in rodents. Studies with MR antagonists suggest a similar role in humans. OBJECTIVE The objective of the study was to establish whether loss-of-function mutations in NR3C2, encoding MR, cause activation of the HPA axis. DESIGN AND SETTING This was a case-control study in members of pedigrees from the PHA1.NET cohort, comprising patients with pseudohypoaldosteronism type 1 (PHA1) who are heterozygous for loss-of-function mutations in NR3C2 and healthy controls who are unaffected family members. PARTICIPANTS Twelve adult patients with PHA1 (six men, six women) and 20 age-matched healthy controls (seven men, 13 women) participated in the study. RESULTS Patients with PHA1 had higher morning plasma cortisol (816 ± 85 vs 586 ± 50 nmol/L, P = .02) and increased 24-hour urinary excretion of cortisol metabolites (985 ± 150 vs 640 ± 46 μg/mmol creatinine, P = .03), independently of gender. After adjustment for gender, age, PHA1 diagnosis, and percentage body fat, higher plasma cortisol was associated with higher plasma renin, lower serum high-density lipoprotein-cholesterol, and higher waist circumference but not with blood pressure, carotid intima-media thickness, or echocardiographic parameters. CONCLUSIONS Haploinsufficiency of MR in PHA1 causes HPA axis activation, providing genetic evidence that MR contributes to negative feedback in the human HPA axis. With limited sample size, initial indications suggest the resulting hypercortisolemia is related to the severity of MR deficiency and has adverse effects mediated by glucocorticoid receptors on liver lipid metabolism and adipose tissue distribution but does not adversely affect cardiac and vascular remodeling in the absence of normal signaling through the MR.
Collapse
Affiliation(s)
- Brian R Walker
- British Heart Foundation Centre for Cardiovascular Science (B.R.W., R.A.), Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom; Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat-Claude Bernard, 75018 Paris, France; Unité Mixte de Recherche 1138 (B.E.), INSERM, Centre de Recherche des Cordeliers, 75006 Paris, France; Université Paris Diderot (B.E.), Sorbonne Paris Cité, 75018 Paris, France; Unité Mixte de Recherche en Santé 970 (M.-C.Z.), INSERM, Paris Cardiovascular Research Center, 75015 Paris, France; University Paris Descartes (M.-C.Z.), Sorbonne Paris Cité, 75006 Paris, France; and Assistance Publique-Hôpitaux de Paris (M.-C.Z.), Hôpital Européen Georges Pompidou, Service de Génétique, 75015 Paris, France
| | | | | | | |
Collapse
|
22
|
Sacre K, Escoubet B, Pasquet B, Chauveheid MP, Zennaro MC, Tubach F, Papo T. Increased arterial stiffness in systemic lupus erythematosus (SLE) patients at low risk for cardiovascular disease: a cross-sectional controlled study. PLoS One 2014; 9:e94511. [PMID: 24722263 PMCID: PMC3983200 DOI: 10.1371/journal.pone.0094511] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 03/17/2014] [Indexed: 11/19/2022] Open
Abstract
Cardiovascular disease (CVD) is a major cause of death in systemic lupus erythematosus (SLE) patients. Although the risk for cardiovascular events in patients with SLE is significant, the absolute number of events per year in any given cohort remains small. Thus, CVD risks stratification in patients with SLE focuses on surrogate markers for atherosclerosis at an early stage, such as reduced elasticity of arteries. Our study was designed to determine whether arterial stiffness is increased in SLE patients at low risk for CVD and analyze the role for traditional and non-traditional CVD risk factors on arterial stiffness in SLE. Carotid-femoral pulse wave velocity (PWV) was prospectively assessed as a measure of arterial stiffness in 41 SLE patients and 35 controls (CTL). Adjustment on age or Framingham score was performed using a logistic regression model. Factors associated with PWV were identified separately in SLE patients and in controls using Pearson's correlation coefficient for univariate analysis and multiple linear regression for multivariate analysis. SLE patients and controls displayed a low 10-year risk for CVD according to Framingham score (1.8±3.6% in SLE vs 1.6±2.8% in CTL, p = 0.46). Pulse wave velocity was, however, higher in SLE patients (7.1±1.6 m/s) as compared to controls (6.3±0.8 m/s; p = 0.01, after Framingham score adjustment) and correlated with internal carotid wall thickness (p = 0.0017). In multivariable analysis, only systolic blood pressure (p = 0.0005) and cumulative dose of glucocorticoids (p = 0.01) were associated with PWV in SLE patients. Interestingly, the link between systolic blood pressure (SBP) and arterial stiffness was also confirmed in SLE patients with normal systolic blood pressure. In conclusion, arterial stiffness is increased in SLE patients despite a low risk for CVD according to Framingham score and is associated with systolic blood pressure and glucocorticoid therapy.
Collapse
Affiliation(s)
- Karim Sacre
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
- INSERM U1149, Paris, France
- Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France
- * E-mail:
| | - Brigitte Escoubet
- Département de Physiologie, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U1138, Paris, France
| | - Blandine Pasquet
- Département d'Epidémiologie et Recherche Clinique, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM CIE 801, Paris, France
| | - Marie-Paule Chauveheid
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Maria-Christina Zennaro
- Département de Cardiologie, Hôpital Européen Georges Pompidou, Université Paris Descartes, PRES Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, INSERM, UMRS 970, Paris, France
| | - Florence Tubach
- Département d'Epidémiologie et Recherche Clinique, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM CIE 801, Paris, France
| | - Thomas Papo
- Département de Médecine Interne, Hôpital Bichat, Université Paris Diderot, PRES Sorbonne Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
- INSERM U1149, Paris, France
- Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and Remodelling in Renal and Respiratory Diseases), Paris, France
| |
Collapse
|
23
|
Monceau V, Llach A, Azria D, Bridier A, Petit B, Mazevet M, Strup-Perrot C, To THV, Calmels L, Germaini MM, Gourgou S, Fenoglietto P, Bourgier C, Gomez AM, Escoubet B, Dörr W, Haagen J, Deutsch E, Morel E, Vozenin MC. Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis. Radiother Oncol 2014; 111:63-71. [PMID: 24721545 DOI: 10.1016/j.radonc.2014.01.025] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Revised: 01/06/2014] [Accepted: 01/28/2014] [Indexed: 01/22/2023]
Abstract
BACKGROUND Cardiac toxicity is a side-effect of anti-cancer treatment including radiotherapy and this translational study was initiated to characterize radiation-induced cardiac side effects in a population of breast cancer patients and in experimental models in order to identify novel therapeutic target. METHODS The size of the heart was evaluated in CO-HO-RT patients by measuring the Cardiac-Contact-Distance before and after radiotherapy (48months of follow-up). In parallel, fibrogenic signals were studied in a severe case of human radiation-induced pericarditis. Lastly, radiation-induced cardiac damage was studied in mice and in rat neonatal cardiac cardiomyocytes. RESULTS In patients, time dependent enhancement of the CCD was measured suggesting occurrence of cardiac hypertrophy. In the case of human radiation-induced pericarditis, we measured the activation of fibrogenic (CTGF, RhoA) and remodeling (MMP2) signals. In irradiated mice, we documented decreased contractile function, enlargement of the ventricular cavity and long-term modification of the time constant of decay of Ca(2+) transients. Both hypertrophy and amyloid deposition were correlated with the induction of Epac-1; whereas radiation-induced fibrosis correlated with Rho/CTGF activation. Transactivation studies support Epac contribution in hypertrophy stimulation and showed that radiotherapy and Epac displayed specific and synergistic signals. CONCLUSION Epac-1 has been identified as a novel regulator of radiation-induced hypertrophy and amyloidosis but not fibrosis in the heart.
Collapse
Affiliation(s)
- Virginie Monceau
- INSERM U1030, LabEx LERMIT, Villejuif, France; Faculté de Médecine Paris-Sud, Université Paris-Sud 11, Le Kremlin-Bicêtre, France
| | - Anna Llach
- INSERM U769, IFR141, LabEx LERMIT, Faculté de Pharmacie, Châtenay-Malabry, France
| | - David Azria
- Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France
| | - André Bridier
- Département de radiothérapie, Institut Gustave Roussy, Villejuif, France
| | - Benoît Petit
- INSERM U1030, LabEx LERMIT, Villejuif, France; Faculté de Médecine Paris-Sud, Université Paris-Sud 11, Le Kremlin-Bicêtre, France
| | - Marianne Mazevet
- INSERM U769, IFR141, LabEx LERMIT, Faculté de Pharmacie, Châtenay-Malabry, France
| | | | - Thi-Hong-Van To
- INSERM U1030, LabEx LERMIT, Villejuif, France; Faculté de Médecine Paris-Sud, Université Paris-Sud 11, Le Kremlin-Bicêtre, France
| | - Lucie Calmels
- Département de radiothérapie, Institut Gustave Roussy, Villejuif, France
| | | | - Sophie Gourgou
- Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France
| | - Pascal Fenoglietto
- Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France
| | - Céline Bourgier
- INSERM U1030, LabEx LERMIT, Villejuif, France; Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France; Département de radiothérapie, Institut Gustave Roussy, Villejuif, France
| | - Ana-Maria Gomez
- INSERM U769, IFR141, LabEx LERMIT, Faculté de Pharmacie, Châtenay-Malabry, France
| | - Brigitte Escoubet
- Département de Physiologie, Explorations Fonctionnelles, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, France; Université Paris Diderot, France; INSERM U872, Paris, France
| | - Wolfgang Dörr
- Department of Radiotherapy and Radiation Oncology, Technical University, Dresden, Germany; Department of Radiation Oncology & Christian Doppler Laboratory for Medical Radiation Research in Radiooncology Medical University, Vienna, Austria
| | - Julia Haagen
- Department of Radiotherapy and Radiation Oncology, Technical University, Dresden, Germany
| | - Eric Deutsch
- INSERM U1030, LabEx LERMIT, Villejuif, France; Faculté de Médecine Paris-Sud, Université Paris-Sud 11, Le Kremlin-Bicêtre, France; Département de radiothérapie, Institut Gustave Roussy, Villejuif, France
| | - Eric Morel
- INSERM U769, IFR141, LabEx LERMIT, Faculté de Pharmacie, Châtenay-Malabry, France
| | - Marie Catherine Vozenin
- INSERM U1030, LabEx LERMIT, Villejuif, France; Faculté de Médecine Paris-Sud, Université Paris-Sud 11, Le Kremlin-Bicêtre, France; Laboratoire de Radio-oncologie, CHUV, Lausanne, Switzerland.
| |
Collapse
|
24
|
Slove S, Lannoy M, Behmoaras J, Pezet M, Sloboda N, Lacolley P, Escoubet B, Buján J, Jacob MP. Potassium channel openers increase aortic elastic fiber formation and reverse the genetically determined elastin deficit in the BN rat. Hypertension 2013; 62:794-801. [PMID: 23918751 DOI: 10.1161/hypertensionaha.113.01379] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hypertension is a cardiovascular disorder that appears in more than half of the patients with Williams-Beuren syndrome, hemizygous for the elastin gene among 26 to 28 other genes. It was shown that the antihypertensive drug minoxidil, an ATP-dependent potassium channel opener, enhances elastic fiber formation; however, no wide clinical application was developed because of its adverse side effects. The Brown Norway rat was used here as an arterial elastin-deficient model. We tested 3 different potassium channel openers, minoxidil, diazoxide, and pinacidil, and 1 potassium channel blocker, glibenclamide, on cultured smooth muscle cells from Brown Norway rat aorta. All tested potassium channel openers increased mRNAs encoding proteins and enzymes involved in elastic fiber formation, whereas glibenclamide had the opposite effect. The higher steady-state level of tropoelastin mRNA in minoxidil-treated cells was attributable to an increase in both transcription and mRNA stability. Treatment of Brown Norway rats for 10 weeks with minoxidil or diazoxide increased elastic fiber content and decreased cell number in the aortic media, without changing collagen content. The minoxidil-induced cardiac hypertrophy was reduced when animals simultaneously received irbesartan, an angiotensin II-receptor antagonist. This side effect of minoxidil was not observed in diazoxide-treated animals. In conclusion, diazoxide, causing less undesirable side effects than minoxidil, or coadministration of minoxidil and irbesartan, increases elastic fiber content, decreases cell number in the aorta and, thus, could be suitable for treating vascular pathologies characterized by diminished arterial elastin content and simultaneous hypertension.
Collapse
Affiliation(s)
- Séverin Slove
- CHU Xavier Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Escoubet B, Couffignal C, Laisy JP, Mangin L, Chillon S, Laouénan C, Serfaty JM, Jeunemaitre X, Mentré F, Zennaro MC. Cardiovascular Effects of Aldosterone. ACTA ACUST UNITED AC 2013; 6:381-90. [DOI: 10.1161/circgenetics.113.000115] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Background—
High plasma aldosterone has deleterious cardiovascular effects that are independent of blood pressure, but the role of the mineralocorticoid receptor remains unclear. Renal pseudohypoaldosteronism type 1 is a rare autosomal-dominant disease caused by
NR3C2
loss-of-function mutations, which is characterized by renal salt loss and compensatory high renin and aldo secretion. We aimed to assess the cardiovascular outcomes in adults carrying NR3C2 mutations.
Methods and Results—
In this case-control study, 39
NR3C2
mutation carriers were compared with sex- and age-paired noncarriers. Patients underwent cardiac and vascular ultrasound, cardiac MRI with gadolinium injection, measurement of pulse wave velocity, extracellular water, 24-hour ambulatory blood pressure, and autonomous nervous system activity. Mutation carriers showed increased aldo and renin plasma levels (4.5- and 1.6-fold, respectively;
P
<0.0001), together with increased salt appetite (1.8-fold;
P
=0.002), with normal extracellular water and blood pressure, and no autonomous nervous system activation. Cardiac and vascular parameters were not significantly different between mutation carriers and noncarriers (no left ventricular remodeling or fibrosis, normal left ventricular systolic function, and aorta stiffness). Tissue Doppler showed better diastolic left ventricular function in mutation carriers (e′,
P
=0.001; E/e′,
P
=0.003). Mutation carriers had significantly more frequent history of slow body weight recovery at birth, symptomatic hypotension, and miscarriage in women.
Conclusions—
Despite life-long increase in plasma aldosterone and renin levels, no adverse cardiovascular outcome occurred in pseudohypoaldosteronism type 1, but rather an improved diastolic left ventricular function. This suggests that the cardiovascular consequences of aldosterone excess require full mineralocorticoid receptor signaling.
Clinical Trial Registration—
http://www.clinicaltrials.gov
; unique identifier: NCT00646828.
Collapse
Affiliation(s)
- Brigitte Escoubet
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Camille Couffignal
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Jean-Pierre Laisy
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Laurence Mangin
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Sylvie Chillon
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Cédric Laouénan
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Jean-Michel Serfaty
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Xavier Jeunemaitre
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - France Mentré
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| | - Maria-Christina Zennaro
- From the Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (B.E., C.C., J.-P.L., L.M., S.C., C.L., J.-M.S., F.M.); Université Paris Diderot, Sorbonne Paris Cité (B.E., C.C., J.-P.L., L.M., C.L., J.-M.S., F.M.); Inserm, UMR 872, Centre de Recherche des Cordeliers CRC (B.E.); Inserm UMR-S 738 (C.C., C.L., F.M.); Laboratoire Matière et Systèmes Complexes, UMR-7057 CNRS (L.M.); Inserm, UMR 970 Paris Cardiovascular Research Centre (X.J., M.-C.Z.); Assistance Publique
| |
Collapse
|
26
|
Sacre K, Escoubet B, Chauchard M, Chauveheid MP, Zennaro MC, Papo T. FRI0277 Arterial stiffness in systemic lupus erythematosus (SLE) patients: a controlled study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Sacre K, Escoubet B, Charles N, Chauveheid MP, Papo T. THU0341 Expansion of CD4+CXCR3+ T Cells in Patients with Systemic Lupus Erythematosus (SLE) Correlates with Subclinical Atherosclerosis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
El Hasnaoui-Saadani R, Marchant D, Pichon A, Escoubet B, Pezet M, Hilfiker-Kleiner D, Hoch M, Pham I, Quidu P, Voituron N, Journé C, Richalet JP, Favret F. Epo deficiency alters cardiac adaptation to chronic hypoxia. Respir Physiol Neurobiol 2013; 186:146-54. [DOI: 10.1016/j.resp.2013.01.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 12/21/2012] [Accepted: 01/08/2013] [Indexed: 02/04/2023]
|
29
|
Tritsch E, Mallat Y, Lefebvre F, Diguet N, Escoubet B, Blanc J, De Windt LJ, Catalucci D, Vandecasteele G, Li Z, Mericskay M. An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc Res 2013; 98:372-80. [PMID: 23436819 DOI: 10.1093/cvr/cvt042] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
AIMS The expression of the sodium/calcium exchanger NCX1 increases during cardiac hypertrophy and heart failure, playing an important role in Ca(2+) extrusion. This increase is presumed to result from stress signalling induced changes in the interplay between transcriptional and post-transcriptional regulations. We aimed to determine the impact of the SRF transcription factor known to regulate the NCX1 promoter and microRNA genes, on the expression of NCX1 mRNA and protein and annexin A5 (AnxA5), a Ca(2+)-binding protein interacting with NCX1 and increased during HF. METHODS AND RESULTS NCX1 mRNA was decreased while the protein was increased in the failing heart of the cardiomyocyte-restricted SRF knock-out mice (SRF(HKO)). The induction of NCX1 mRNA by the pro-hypertrophic drug phenylephrine observed in control mice was abolished in the SRF(HKO) though the protein was strongly increased. AnxA5 protein expression profile paralleled the expression of NCX1 protein in the SRF(HKO). MiR-1, a microRNA regulated by SRF, was decreased in the SRF(HKO) and repressed by phenylephrine. In vitro and in vivo manipulation of miR-1 levels and site-directed mutagenesis showed that NCX1 and AnxA5 mRNAs are targets of miR-1. AnxA5 overexpression slowed down Ca(2+) extrusion during caffeine application in adult rat cardiomyocytes. CONCLUSION Our study reveals the existence of a complex regulatory loop where SRF regulates the transcription of NCX1 and miR-1, which in turn functions as a rheostat limiting the translation of NCX1 and AnxA5 proteins. The decrease of miR-1 and increase of AnxA5 appear as important modulators of NCX1 expression and activity during heart failure.
Collapse
Affiliation(s)
- Eva Tritsch
- Department of Aging, Stress and Inflammation , UPMC Univ Paris 6, 7, quai Saint Bernard - BP 256, Paris 75005, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Monceau V, Meziani L, Strup-Perrot C, Morel E, Schmidt M, Haagen J, Escoubet B, Dörr W, Vozenin MC. Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis. PLoS One 2013; 8:e57052. [PMID: 23451141 PMCID: PMC3579799 DOI: 10.1371/journal.pone.0057052] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Accepted: 01/17/2013] [Indexed: 12/15/2022] Open
Abstract
Aim Investigating long-term cardiac effects of low doses of ionizing radiation is highly relevant in the context of interventional cardiology and radiotherapy. Epidemiological data report that low doses of irradiation to the heart can result in significant increase in the cardiovascular mortality by yet unknown mechanisms. In addition co-morbidity factor such as hypertension or/and atherosclerosis can enhance cardiac complications. Therefore, we explored the mechanisms that lead to long-term cardiac remodelling and investigated the interaction of radiation-induced damage to heart and cardiovascular systems with atherosclerosis, using wild-type and ApoE-deficient mice. Methods and Results ApoE−/− and wild-type mice were locally irradiated to the heart at 0, 0.2 and 2 Gy (RX). Twenty, 40 and 60 weeks post-irradiation, echocardiography were performed and hearts were collected for cardiomyocyte isolation, histopathological analysis, study of inflammatory infiltration and fibrosis deposition. Common and strain-specific pathogenic pathways were found. Significant alteration of left ventricular function (eccentric hypertrophy) occurred in both strains of mice. Low dose irradiation (0.2 Gy) induced premature death in ApoE−/− mice (47% died at 20 weeks). Acute inflammatory infiltrate was observed in scarring areas with accumulation of M1-macrophages and secretion of IL-6. Increased expression of the fibrogenic factors (TGF-β1 and PAI-1) was measured earlier in cardiomyocytes isolated from ApoE−/− than in wt animals. Conclusion The present study shows that cardiac exposure to low dose of ionizing radiation induce significant physiological, histopathological, cellular and molecular alterations in irradiated heart with mild functional impairment. Atherosclerotic predisposition precipitated cardiac damage induced by low doses with an early pro-inflammatory polarization of macrophages.
Collapse
|
31
|
Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserrat L, Namdar M, Weidemann F. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2012; 34:802-8. [PMID: 22736678 PMCID: PMC3596758 DOI: 10.1093/eurheartj/ehs166] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- Zaheer Yousef
- Department of Cardiology, University Hospital of Wales, Cardiff CF14 4XW, UK.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Nguyen Dinh Cat A, Escoubet B, Agrapart V, Griol-Charhbili V, Schoeb T, Feng W, Jaimes E, Warnock DG, Jaisser F. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease. PLoS One 2012; 7:e33743. [PMID: 22574107 PMCID: PMC3344819 DOI: 10.1371/journal.pone.0033743] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Accepted: 02/16/2012] [Indexed: 11/19/2022] Open
Abstract
Fabry disease is an X-linked disorder of glycosphingolipid metabolism that results in progressive accumulation of neutral glycosphingolipids, (predominately globotriaosylceramide; GL-3) in lysosomes, as well as other cellular compartments and the extracellular space. Our aim was to characterize the cardiac phenotype of male knock-out mice that are deficient in alpha-galactosidase A activity, as a model for Fabry disease and test the efficacy of Enzyme Replacement Therapy with agalsidase-beta. Male mice (3–4 months of age) were characterized with awake blood pressure and heart rate measurements, cardiac echocardiography and electrocardiography measurements under light anesthesia, histological studies and molecular studies with real-time polymerase chain reaction. The Fabry knock-out mouse has bradycardia and lower blood pressure than control wild type (CB7BL/6J) mice. In Fabry knock-out mice, the cardiomyopathy associated mild hypertrophy at echography with normal systolic LV function and mild diastolic dysfunction. Premature atrial contractions were more frequent in without conduction defect. Heart weight normalized to tibial length was increased in Fabry knock-out mice. Ascending aorta dilatation was observed. Molecular studies were consistent with early stages of cardiac remodeling. A single dose of agalsidase-beta (3 mg/kg) did not affect the LV hypertrophy, function or heart rate, but did improve the mRNA signals of early cardiac remodeling. In conclusion, the alpha-galactosidase A deficient mice at 3 to 4 months of age have cardiac and vascular alterations similar to that described in early clinical stage of Fabry disease in children and adolescents. Enzyme replacement therapy affects cardiac molecular remodeling after a single dose.
Collapse
Affiliation(s)
| | - Brigitte Escoubet
- Inserm U872 Team 1, Paris, France
- AP-HP Hôpital Bichat, Paris, France
- Centre d’Explorations Fonctionnelles-Imagerie, Bichat Federative Research Institute 02, University Denis Diderot, Paris, France
| | - Vincent Agrapart
- Inserm U872 Team 1, Paris, France
- University Pierre et Marie Curie, Paris, France
| | | | - Trenton Schoeb
- University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - Wenguang Feng
- University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - Edgar Jaimes
- University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - David G. Warnock
- University of Alabama at Birmingham, Birmingham, Alabama, United States of America
| | - Frederic Jaisser
- Inserm U872 Team 1, Paris, France
- University Pierre et Marie Curie, Paris, France
- * E-mail:
| |
Collapse
|
33
|
Touvron M, Escoubet B, Mericskay M, Angelini A, Lamotte L, Santini MP, Rosenthal N, Daegelen D, Tuil D, Decaux JF. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Dis Model Mech 2012; 5:481-91. [PMID: 22563064 PMCID: PMC3380711 DOI: 10.1242/dmm.009456] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Cardiac fibrosis is critically involved in the adverse remodeling accompanying dilated cardiomyopathies (DCMs), which leads to cardiac dysfunction and heart failure (HF). Connective tissue growth factor (CTGF), a profibrotic cytokine, plays a key role in this deleterious process. Some beneficial effects of IGF1 on cardiomyopathy have been described, but its potential role in improving DCM is less well characterized. We investigated the consequences of expressing a cardiac-specific transgene encoding locally acting IGF1 propeptide (muscle-produced IGF1; mIGF1) on disease progression in a mouse model of DCM [cardiac-specific and inducible serum response factor (SRF) gene disruption] that mimics some forms of human DCM. Cardiac-specific mIGF1 expression substantially extended the lifespan of SRF mutant mice, markedly improved cardiac functions, and delayed both DCM and HF. These protective effects were accompanied by an overall improvement in cardiomyocyte architecture and a massive reduction of myocardial fibrosis with a concomitant amelioration of inflammation. At least some of the beneficial effects of mIGF1 transgene expression were due to mIGF1 counteracting the strong increase in CTGF expression within cardiomyocytes caused by SRF deficiency, resulting in the blockade of fibroblast proliferation and related myocardial fibrosis. These findings demonstrate that SRF plays a key role in the modulation of cardiac fibrosis through repression of cardiomyocyte CTGF expression in a paracrine fashion. They also explain how impaired SRF function observed in human HF promotes fibrosis and adverse cardiac remodeling. Locally acting mIGF1 efficiently protects the myocardium from these adverse processes, and might thus represent a therapeutic avenue to counter DCM.
Collapse
|
34
|
Messaoudi S, Zhang AD, Griol-Charhbili V, Escoubet B, Sadoshima J, Farman N, Jaisser F. The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling. PLoS One 2012; 7:e30156. [PMID: 22291909 PMCID: PMC3264592 DOI: 10.1371/journal.pone.0030156] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Accepted: 12/11/2011] [Indexed: 01/10/2023] Open
Abstract
Experimental and clinical studies have shown that aldosterone/mineralocorticoid receptor (MR) activation has deleterious effects in the cardiovascular system; however, the signalling pathways involved in the pathophysiological effects of aldosterone/MR in vivo are not fully understood. Several in vitro studies suggest that Epidermal Growth Factor Receptor (EGFR) plays a role in the cardiovascular effects of aldosterone. This hypothesis remains to be demonstrated in vivo. To investigate this question, we analyzed the molecular and functional consequences of aldosterone exposure in a transgenic mouse model with constitutive cardiomyocyte-specific overexpression of a mutant EGFR acting as a dominant negative protein (DN-EGFR). As previously reported, Angiotensin II-mediated cardiac remodelling was prevented in DN-EGFR mice. However, when chronic MR activation was induced by aldosterone-salt-uninephrectomy, cardiac hypertrophy was similar between control littermates and DN-EGFR. In the same way, mRNA expression of markers of cardiac remodelling such as ANF, BNF or β-Myosin Heavy Chain as well as Collagen 1a and 3a was similarly induced in DN-EGFR mice and their CT littermates. Our findings confirm the role of EGFR in AngII mediated cardiac hypertrophy, and highlight that EGFR is not involved in vivo in the damaging effects of aldosterone on cardiac function and remodelling.
Collapse
Affiliation(s)
- Smail Messaoudi
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Pierre et Marie Curie University, Paris VI, Paris, France
| | - An Di Zhang
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Pierre et Marie Curie University, Paris VI, Paris, France
| | - Violaine Griol-Charhbili
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Pierre et Marie Curie University, Paris VI, Paris, France
| | - Brigitte Escoubet
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France
- University Denis Diderot, Paris 7, Paris, France
| | - Junichi Sadoshima
- Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
| | - Nicolette Farman
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Pierre et Marie Curie University, Paris VI, Paris, France
| | - Frederic Jaisser
- INSERM, U872, Centre de Recherche des Cordeliers, Paris, France
- Pierre et Marie Curie University, Paris VI, Paris, France
- * E-mail:
| |
Collapse
|
35
|
Hubert EL, Teissier R, Fernandes-Rosa FL, Fay M, Rafestin-Oblin ME, Jeunemaitre X, Metz C, Escoubet B, Zennaro MC. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol 2011; 22:1997-2003. [PMID: 21903996 DOI: 10.1681/asn.2011030245] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease of mineralocorticoid resistance characterized by salt wasting and failure to thrive in infancy. Here we describe the first case of a newborn with severe recessive PHA1 caused by two heterozygous mutations in NR3C2, gene coding for the mineralocorticoid receptor (MR). Independent segregation of the mutations occurred in the family, with p.Ser166X being transmitted from the affected father and p.Trp806X from the asymptomatic mother Whereas the truncated MR(166X) protein was degraded, MR(806X) was expressed both at the mRNA and protein level. Functional studies demonstrated that despite its inability to bind aldosterone, MR(806X) had partial ligand-independent transcriptional activity. Partial nuclear localization of MR(806X) in the absence of hormone was identified as a prerequisite to initiate transcription. This exceptional case broadens the spectrum of clinical phenotypes of PHA1 and demonstrates that minimal residual activity of MR is compatible with life. It also suggests that rare hypomorphic NR3C2 alleles may be more common than expected from the prevalence of detected PHA1 cases. This might prove relevant for patient's care in neonatal salt losing disorders and may affect renal salt handling and blood pressure in the general population.
Collapse
Affiliation(s)
- Edwige-Ludiwyne Hubert
- INSERM, U970, Paris Cardiovascular Research Center - PARCC, 56, rue Leblanc, 75015 Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Bergaya S, Faure S, Baudrie V, Rio M, Escoubet B, Bonnin P, Henrion D, Loirand G, Achard JM, Jeunemaitre X, Hadchouel J. WNK1 regulates vasoconstriction and blood pressure response to α 1-adrenergic stimulation in mice. Hypertension 2011; 58:439-45. [PMID: 21768522 DOI: 10.1161/hypertensionaha.111.172429] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Gain-of-function mutations in the human WNK1 (with-no-lysine[K]1) gene are responsible for a monogenic form of arterial hypertension, and WNK1 polymorphisms have been associated with common essential hypertension. The role of WNK1 in renal ionic reabsorption has been established, but no investigation of its possible influence on vascular tone, an essential determinant of blood pressure, has been performed until now. WNK1 complete inactivation in the mouse is embryonically lethal. We, thus, examined in Wnk1(+/-) haploinsufficient adult mice whether WNK1 could regulate in vivo vascular tone and whether this was correlated with blood pressure variation. Wnk1(+/-) mice displayed a pronounced decrease in blood pressure responses in vivo and in vascular contractions ex vivo following α(1)-adrenergic receptor activation with no change in basal blood pressure and renal function. We also observed a major loss of the pressure-induced contractile (myogenic) response in Wnk1(+/-) arteries associated with a specific alteration of the smooth muscle cell contractile function. These alterations in vascular tone were associated with a decreased phosphorylation level of the WNK1 substrate SPAK (STE20/SPS1-related proline/alanine-rich kinase) and its target NKCC1 (Na(+)-K(+)-2Cl(-) cotransporter 1) in Wnk1(+/-) arteries. Our study identifies a novel and major role for WNK1 in maintaining in vivo blood pressure and vasoconstriction responses specific to α(1)-adrenergic receptor activation. Our findings uncover a vascular signaling pathway linking α(1)-adrenergic receptors and pressure to WNK1, SPAK, and NKCC1 and may, thus, significantly broaden the comprehension of the regulatory mechanisms of vascular tone in arterial hypertension.
Collapse
Affiliation(s)
- Sonia Bergaya
- INSERM U970, Paris Cardiovascular Research Center PARCC, 56 rue Leblanc, 75015 Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuillez C, Jaisser F, Richard V. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011; 300:H2035-43. [PMID: 21441311 DOI: 10.1152/ajpheart.00552.2010] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The deleterious effects of aldosterone excess demonstrated in cardiovascular diseases might be linked in part to coronary vascular dysfunction. However, whether such vascular dysfunction is a cause or a consequence of the changes occurring in the cardiomyocytes is unclear. Moreover, the possible link between mineralocorticoid receptor (MR)-mediated effects on the cardiomyocyte and the coronary arteries is unknown. Thus we used a mouse model with conditional, cardiomyocyte-specific overexpression of human MR (hMR) and observed the effects on endothelial function in isolated coronary segments. hMR overexpression decreased the nitric oxide (NO)-mediated relaxing responses to acetylcholine in coronary arteries (but not in peripheral arteries), and this was prevented by a 1-mo treatment either with an MR antagonist, vitamin E/vitamin C, or a NADPH oxidase inhibitor. hMR overexpression did not affect coronary endothelial NO synthase content nor its level of phosphorylation on serine 1177, but increased cardiac levels of reactive oxygen species, cardiac NADPH oxidase (NOX) activity, and expression of the NOX subunit gp91phox, which was limited to endothelial cells. Thus an increase in hMR activation, restricted to cardiomyocytes, is sufficient to induce a severe coronary endothelial dysfunction. We suggest a new paracrine mechanism by which cardiomyocytes trigger a NOX-dependent, reactive oxygen species-mediated coronary endothelial dysfunction.
Collapse
Affiliation(s)
- Julie Favre
- Inserm U644, UFR Médecine-Pharmacie, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Mariko B, Pezet M, Escoubet B, Bouillot S, Andrieu JP, Starcher B, Quaglino D, Jacob MP, Huber P, Ramirez F, Faury G. Fibrillin-1 genetic deficiency leads to pathological ageing of arteries in mice. J Pathol 2011; 224:33-44. [PMID: 21432852 DOI: 10.1002/path.2840] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2010] [Revised: 11/11/2010] [Accepted: 12/06/2010] [Indexed: 02/02/2023]
Abstract
Fibrillin-1, the major component of extracellular microfibrils that associate with insoluble elastin in elastic fibres, is mainly synthesized during development and postnatal growth and is believed to guide elastogenesis. Mutations in the fibrillin-1 gene cause Marfan syndrome, a multisystem disorder characterized by aortic aneurysms and dissections. The recent finding that early deficiency of elastin modifies vascular ageing has raised the possibility that fibrillin-1 deficiency could also contribute to late-onset pathology of vascular remodelling. To address this question, we examined cardiovascular function in 3-week-old, 6-month-old, and 24-month-old mice that are heterozygous for a hypomorphic structural mutation of fibrillin-1 (Fbn1{+/mgΔ} mice). Our results indicate that Fbn1{+/mgΔ} mice, particularly those that are 24 months old, are slightly more hypotensive than wild-type littermates. Additionally, aneurysm and aortic insufficiency were more frequently observed in ageing Fbn1{+/mgΔ}$ mice than in the wild-type counterparts. We also noted substantial fragmentation and decreased number of elastic lamellae in the aortic wall of Fbn1{+/mgΔ} mice, which were correlated with an increase in aortic stiffness, a decrease in vasoreactivity, altered expression of elastic fibre-related genes, including fibrillin-1 and elastin, and a decrease in the relative ratio between tissue elastin and collagen. Collectively, our findings suggest that the heterozygous mgΔ mutation accelerates some aspects of vascular ageing and eventually leads to aortic manifestations resembling those of Marfan syndrome. Importantly, our data also indicate that vascular abnormalities in Fbn1{+/mgΔ} mice are opposite to those induced by elastin haploinsufficiency during ageing that affect blood pressure, vascular dimensions, and number of elastic lamellae.
Collapse
|
39
|
Khouzami L, Bourin MC, Christov C, Damy T, Escoubet B, Caramelle P, Perier M, Wahbi K, Meune C, Pavoine C, Pecker F. Delayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic glutathione resource. Am J Pathol 2010; 177:1356-64. [PMID: 20696779 DOI: 10.2353/ajpath.2010.090479] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Oxidative stress contributes to the pathogenesis of Duchenne muscular dystrophy (DMD). Although they have been a model for DMD, mdx mice exhibit slowly developing cardiomyopathy. We hypothesized that disease process was delayed owing to the development of an adaptive mechanism against oxidative stress, involving glutathione synthesis. At 15 to 20 weeks of age, mdx mice displayed a 33% increase in blood glutathione levels compared with age-matched C57BL/6 mice. In contrast, cardiac glutathione content was similar in mdx and C57BL/6 mice as a result of the balanced increased expression of glutamate cysteine ligase catalytic and regulatory subunits ensuring glutathione synthesis in the mdx mouse heart, as well as increased glutathione peroxidase-1 using glutathione. Oral administration from 10 weeks of age of the glutamate cysteine ligase inhibitor, l-buthionine(S,R)-sulfoximine (BSO, 5 mmol/L), led to a 33% and 50% drop in blood and cardiac glutathione, respectively, in 15- to 20-week-old mdx mice. Moreover, 20-week-old BSO-treated mdx mice displayed left ventricular hypertrophy associated with diastolic dysfunction, discontinuities in beta-dystroglycan expression, micronecrosis and microangiopathic injuries. Examination of the glutathione status in four DMD patients showed that three displayed systemic glutathione deficiency as well. In conclusion, low glutathione resource hastens the onset of cardiomyopathy linked to a defect in dystrophin in mdx mice. This is relevant to the glutathione deficiency that DMD patients may suffer.
Collapse
Affiliation(s)
- Lara Khouzami
- Institut National de la Santé et de la Recherche Médicale, Institut Mondor de Recherche Biomédicale, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sacré K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, Lidove O, Laissy JP, Papo T. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. ACTA ACUST UNITED AC 2010; 62:2093-100. [PMID: 20506512 DOI: 10.1002/art.27488] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI). METHODS Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS. RESULTS Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6%) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1%). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean +/- SD 5.1 +/- 8.2% and 6.5 +/- 7.6%, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-beta(2)-glycoprotein I antibodies. CONCLUSION The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.
Collapse
Affiliation(s)
- Karim Sacré
- Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, and Paris 7 University, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Brihaye B, Lidove O, Sacré K, Laissy JP, Escoubet B, Valla D, Papo T. Diffuse periarterial involvement in systemic fibrosclerosis with Riedel's thyroiditis, sclerosing cholangitis, and retroperitoneal fibrosis. Scand J Rheumatol 2009; 37:490-2. [DOI: 10.1080/03009740802241725] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Clairotte C, Retout S, Potier L, Roussel R, Escoubet B. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. Diabetes Care 2009; 32:1231-6. [PMID: 19366974 PMCID: PMC2699730 DOI: 10.2337/dc08-2230] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Peripheral arterial disease (PAD) is a prognostic marker in cardiovascular disease. The use of Doppler-measured ankle-brachial pressure index (Dop-ABI) for PAD diagnosis is limited because of time, required training, and costs. We assessed automated oscillometric measurement of the ankle-brachial pressure index (Osc-ABI) by nurses and clinical staff. RESEARCH DESIGN AND METHODS Clinical staff obtained Osc-ABI with an automated oscillometric device in 146 patients (83 with diabetes) at the time of Dop-ABI measurement and ultrasound evaluation. RESULTS Measurements were obtained in most legs (Dop-ABI 98%; Osc-ABI 95.5%). Dop- and Osc-ABI were significantly related in diabetic and nondiabetic patients with good agreement over a wide range of values. When Dop-ABI <or=0.90 was used as the gold standard for PAD, receiver operating characteristic curve analysis showed that PAD was accurately diagnosed with Osc-ABI in diabetic patients. When ultrasound was used to define PAD, Dop-ABI had better diagnostic performance than Osc-ABI in the whole population and in diabetic patients (P = 0.026). Both methods gave similar results in nondiabetic patients. The cutoff values for the highest sensitivity and specificity for PAD screening were between 1.0 and 1.1. Estimation of cost with the French medical care system fees showed a potential reduction by three of the screening procedures. CONCLUSIONS PAD screening could be improved by using Osc-ABI measured by clinical staff with the benefit of greater cost-effectiveness but at the risk of lower diagnostic performance in diabetic patients.
Collapse
Affiliation(s)
- Cécile Clairotte
- Département de Physiologie-Explorations Fonctionnelles, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France
| | | | | | | | | |
Collapse
|
43
|
Sorbets E, Delorme L, Fornasa G, Meilhac O, Escoubet B, Bardon J, Feldman LJ, Caligiuri G. A014 Valeur diagnostique de la fraction tronquée du CD31 plasmatique dans la cardiopathie ischemique. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72147-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Slove S, Pellay FX, Pezet M, Escoubet B, Behmoaras J, Gauguier D, Bujan J, Benecke A, Jacob MP. L010 Synthèse de l’élastine dans l’aorte de rat : étude des gènes régulateurs. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72425-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, Manin S, Deveaux V, Bourin MC, Zimmer A, Lotersztajn S, Pecker F, Pavoine C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 2009; 23:2120-30. [PMID: 19246487 DOI: 10.1096/fj.09-129478] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Post-myocardial infarction (MI) heart failure is a major public health problem in Western countries and results from ischemia/reperfusion (IR)-induced cell death, remodeling, and contractile dysfunction. Ex vivo studies have demonstrated the cardioprotective anti-inflammatory effect of the cannabinoid type 2 (CB2) receptor agonists within hours after IR. Herein, we evaluated the in vivo effect of CB2 receptors on IR-induced cell death, fibrosis, and cardiac dysfunction and investigated the target role of cardiac myocytes and fibroblasts. The infarct size was increased 24 h after IR in CB2(-/-) vs. wild-type (WT) hearts and decreased when WT hearts were injected with the CB2 agonist JWH133 (3 mg/kg) at reperfusion. Compared with WT hearts, CB2(-/-) hearts showed widespread injury 3 d after IR, with enhanced apoptosis and remodeling affecting the remote myocardium. Finally, CB2(-/-) hearts exhibited exacerbated fibrosis, associated with left ventricular dysfunction 4 wk after IR, whereas their WT counterparts recovered normal function. Cardiac myocytes and fibroblasts isolated from CB2(-/-) hearts displayed a higher H(2)O(2)-induced death than WT cells, whereas 1 microM JWH133 triggered survival effects. Furthermore, H(2)O(2)-induced myofibroblast activation was increased in CB2(-/-) fibroblasts but decreased in 1 microM JWH133-treated WT fibroblasts, compared with that in WT cells. Therefore, CB2 receptor activation may protect against post-IR heart failure through direct inhibition of cardiac myocyte and fibroblast death and prevention of myofibroblast activation.
Collapse
|
46
|
Di Zhang A, Cat AND, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling. Hypertension 2008; 52:1060-7. [DOI: 10.1161/hypertensionaha.108.117531] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Experimental and clinical studies show that aldosterone/mineralocorticoid receptor (MR) activation has deleterious effects in the cardiovascular system that may cross-talk with those of angiotensin II (Ang II). This study, using a transgenic mouse model with conditional and cardiomyocyte-restricted overexpression of the human MR, was designed to assess the cardiac consequences of Ang II treatment and cardiomyocyte MR activation. Two-month-old MHCtTA/tetO-hMR double transgenic males (DTg) with conditional, cardiomyocyte-specific human MR expression, and their control littermates were infused with Ang II (200 ng/kg per minute) or vehicle via osmotic minipump. Ang II induced similar increases in systolic blood pressure in control and DTg mice but a greater increase in left ventricle mass/body weight in DTg than in control mice. In DTg mice, Ang II–induced left ventricle hypertrophy and diastolic dysfunction without affecting systolic function, as assessed by echography. These effects were associated with an increase in the expression of collagens and fibronectin, matrix metalloproteinase 2 and matrix metalloproteinase 9 activities, and histological fibrosis. Ang II treatment of DTg mice did not affect inflammation markers, but oxidative stress was substantially increased, as indicated by gp91 expression, apocynin-inhibitable NADPH oxidase activity, and protein carbonylation. These molecular and functional alterations were prevented by pharmacological MR antagonism. Our findings indicate that the effects of Ang II and MR activation in the heart are additive. This observation may be relevant to the clinical use of MR or of combined Ang II type 1 receptor-MR antagonists for hypertrophic cardiomyopathies or for heart failure, particularly when diastolic dysfunction is associated with preserved systolic function.
Collapse
Affiliation(s)
- An Di Zhang
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Aurelie Nguyen Dinh Cat
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Christelle Soukaseum
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Brigitte Escoubet
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Aïcha Cherfa
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Smail Messaoudi
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Claude Delcayre
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Jane-Lise Samuel
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| | - Frederic Jaisser
- From the Inserm U772 (A.D.Z., A.N.D.C., C.S., B.E., F.J.); Collège de France (A.D.Z., A.N.D.C., C.S., F.J.); University Paris Descartes (A.D.Z., A.N.D.C., C.S., S.M., C.D., F.J.); Assistance Publique-Hôpitaux de Paris (B.E.), Hôpital Bichat; University Denis Diderot (B.E., A.C., J.-L.S.); EA 3508 (A.C.); and INSERM U689 (S.M., C.D., J.-L.S.), Paris, France
| |
Collapse
|
47
|
Pezet M, Jacob MP, Escoubet B, Gheduzzi D, Tillet E, Perret P, Huber P, Quaglino D, Vranckx R, Li DY, Starcher B, Boyle WA, Mecham RP, Faury G. Elastin haploinsufficiency induces alternative aging processes in the aorta. Rejuvenation Res 2008; 11:97-112. [PMID: 18173368 DOI: 10.1089/rej.2007.0587] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Elastin, the main component of elastic fibers, is synthesized only in early life and provides the blood vessels with their elastic properties. With aging, elastin is progressively degraded, leading to arterial enlargement, stiffening, and dysfunction. Also, elastin is a key regulator of vascular smooth muscle cell proliferation and migration during development since heterozygous mutations in its gene (Eln) are responsible for a severe obstructive vascular disease, supravalvular aortic stenosis, isolated or associated to Williams syndrome. Here, we have studied whether early elastin synthesis could also influence the aging processes, by comparing the structure and function of ascending aorta from 6- and 24-month-old Eln+/- and Eln+/+ mice. Eln+/- animals have high blood pressure and arteries with smaller diameters and more rigid walls containing additional although thinner elastic lamellas. Nevertheless, longevity of these animals is unaffected. In young adult Eln+/- mice, some features resemble vascular aging of wild-type animals: cardiac hypertrophy, loss of elasticity of the arterial wall through enhanced fragmentation of the elastic fibers, and extracellular matrix accumulation in the aortic wall, in particular in the intima. In Eln+/- animals, we also observed an age-dependent alteration of endothelial vasorelaxant function. On the contrary, Eln+/- mice were protected from several classical consequences of aging visible in aged Eln+/+ mice, such as arterial wall thickening and alteration of alpha(1)-adrenoceptor-mediated vasoconstriction. Our results suggest that early elastin expression and organization modify arterial aging through their impact on both vascular cell physiology and structure and mechanics of blood vessels.
Collapse
Affiliation(s)
- Mylène Pezet
- Université Joseph Fourier, UFR de Biologie, Grenoble, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Gellen B, Fernández-Velasco M, Briec F, Vinet L, LeQuang K, Rouet-Benzineb P, Bénitah JP, Pezet M, Palais G, Pellegrin N, Zhang A, Perrier R, Escoubet B, Marniquet X, Richard S, Jaisser F, Gómez AM, Charpentier F, Mercadier JJ. Conditional FKBP12.6 overexpression in mouse cardiac myocytes prevents triggered ventricular tachycardia through specific alterations in excitation-contraction coupling. Circulation 2008; 117:1778-86. [PMID: 18378612 DOI: 10.1161/circulationaha.107.731893] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Ca(2+) release from the sarcoplasmic reticulum via the ryanodine receptor (RyR2) activates cardiac myocyte contraction. An important regulator of RyR2 function is FKBP12.6, which stabilizes RyR2 in the closed state during diastole. Beta-adrenergic stimulation has been suggested to dissociate FKBP12.6 from RyR2, leading to diastolic sarcoplasmic reticulum Ca(2+) leakage and ventricular tachycardia (VT). We tested the hypothesis that FKBP12.6 overexpression in cardiac myocytes can reduce susceptibility to VT in stress conditions. METHODS AND RESULTS We developed a mouse model with conditional cardiac-specific overexpression of FKBP12.6. Transgenic mouse hearts showed a marked increase in FKBP12.6 binding to RyR2 compared with controls both at baseline and on isoproterenol stimulation (0.2 mg/kg i.p.). After pretreatment with isoproterenol, burst pacing induced VT in 10 of 23 control mice but in only 1 of 14 transgenic mice (P<0.05). In isolated transgenic myocytes, Ca(2+) spark frequency was reduced by 50% (P<0.01), a reduction that persisted under isoproterenol stimulation, whereas the sarcoplasmic reticulum Ca(2+) load remained unchanged. In parallel, peak I(Ca,L) density decreased by 15% (P<0.01), and the Ca(2+) transient peak amplitude decreased by 30% (P<0.001). A 33.5% prolongation of the caffeine-evoked Ca(2+) transient decay was associated with an 18% reduction in the Na(+)-Ca(2+) exchanger protein level (P<0.05). CONCLUSIONS Increased FKBP12.6 binding to RyR2 prevents triggered VT in normal hearts in stress conditions, probably by reducing diastolic sarcoplasmic reticulum Ca(2+) leak. This indicates that the FKBP12.6-RyR2 complex is an important candidate target for pharmacological prevention of VT.
Collapse
|
49
|
Ciobotaru V, Heimburger M, Louedec L, Heymes C, Ventura-Clapier R, Bedossa P, Escoubet B, Michel JB, Mercadier JJ, Logeart D. Effect of Long-Term Heart Rate Reduction by If Current Inhibition on Pressure Overload-Induced Heart Failure in Rats. J Pharmacol Exp Ther 2007; 324:43-9. [PMID: 17901295 DOI: 10.1124/jpet.107.130237] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We investigated the effects of long-term heart rate reduction (HRR) on pressure overload-induced heart failure. Pressure overload of the left ventricle was induced in 21-day-old rats by banding the ascending aorta. HRR was induced for 3 months with ivabradine (n = 44), a selective I(f) current inhibitor, at 10 mg/kg/day, starting 14 days after banding. Thirty-six control banded rats and 16 sham-operated rats received standard chow. Banding resulted in severe left ventricular (LV) hypertrophy (+55% versus shams; p < 0.001) and fibrosis, together with a 34% decrease (p < 0.01) in the LV shortening fraction. Heart rate decreased by 19% in ivabradine-treated rats (p < 0.005 versus controls). Stroke volume increased (by 17%; p < 0.01), whereas cardiac output did not change with HRR. In contrast, HRR resulted in 1) a marked increase in LV filling pressure (p < 0.01) and in atrial, lung, and right ventricular weights (38, 30, and 54%, respectively; p < 0.001); 2) a 50% increase in the incidence of pleural/abdominal effusion (p < 0.001); 3) 7 and 26% increases in LV hypertrophy and fibrosis, respectively (p < 0.05); and 4) a 53% increase in the atrial natriuretic peptide mRNA level compared with controls (p < 0.001). After 3 months of treatment, ivabradine withdrawal normalized the heart rate and reduced LV size and LV filling pressure (p < 0.05). In conclusion, pure longstanding HRR showed no beneficial effect on LV dysfunction in a rat model of pressure overload-induced LV hypertrophy, and it seemed to favor adverse LV remodeling and its congestive consequences.
Collapse
Affiliation(s)
- Vlad Ciobotaru
- Cardiology Department, Lariboisiere Hospital, 2 rue Ambroise Pare, 75010 Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi JL, Corvol P, Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117:1914-25. [PMID: 17607364 PMCID: PMC1890996 DOI: 10.1172/jci28764] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Accepted: 04/24/2007] [Indexed: 01/06/2023] Open
Abstract
The role of the renin-angiotensin system has been investigated by overexpression or inactivation of its different genes in animals. However, there is no data concerning the effect of the constitutive activation of any component of the system. A knockin mouse model has been constructed with a gain-of-function mutant of the Ang II receptor, type 1A (AT(1A)), associating a constitutively activating mutation (N111S) with a C-terminal deletion, which impairs receptor internalization and desensitization. In vivo consequences of this mutant receptor expression in homozygous mice recapitulate its in vitro characteristics: the pressor response is more sensitive to Ang II and longer lasting. These mice present with a moderate (~20 mmHg) and stable increase in BP. They also develop early and progressive renal fibrosis and cardiac fibrosis and diastolic dysfunction. However, there was no overt cardiac hypertrophy. The hormonal parameters (low-renin and inappropriately normal aldosterone productions) mimic those of low-renin human hypertension. This new model reveals that a constitutive activation of AT(1A) leads to cardiac and renal fibrosis in spite of a modest effect on BP and will be useful for investigating the role of Ang II in target organs in a model similar to some forms of human hypertension.
Collapse
Affiliation(s)
- Sandrine Billet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sabine Bardin
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sonia Verp
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Véronique Baudrie
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Annie Michaud
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sophie Conchon
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Martine Muffat-Joly
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Brigitte Escoubet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Evelyne Souil
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ghislaine Hamard
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Kenneth E. Bernstein
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean Marie Gasc
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean-Luc Elghozi
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Pierre Corvol
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Eric Clauser
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|